238 related articles for article (PubMed ID: 29885789)
1. Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
Hu ZY; Xiao H; Xiao M; Tang Y; Sun J; Xie ZM; Ouyang Q
Clin Breast Cancer; 2018 Oct; 18(5):e1149-e1163. PubMed ID: 29885789
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
[TBL] [Abstract][Full Text] [Related]
3. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
[TBL] [Abstract][Full Text] [Related]
4. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.
Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X
Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333
[TBL] [Abstract][Full Text] [Related]
5. The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.
Shao HY; Hao BT; Gao FX
Breast J; 2023; 2023():7028189. PubMed ID: 38021219
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
[TBL] [Abstract][Full Text] [Related]
7. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis.
Li Z; Wu Q; Song J; Zhang Y; Zhu S; Sun S
Horm Cancer; 2018 Jun; 9(3):197-204. PubMed ID: 29556910
[TBL] [Abstract][Full Text] [Related]
8. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
9. Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.
Liu J; Hu Z; Feng Y; Zeng S; Zhong M
Medicine (Baltimore); 2018 Sep; 97(39):e12603. PubMed ID: 30278574
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
[TBL] [Abstract][Full Text] [Related]
11. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
13. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
14. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study.
Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L
Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186
[TBL] [Abstract][Full Text] [Related]
15. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
16. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
17. Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.
Serra P; Sanz-Santos J; Castellà E; Cirauqui B; Andreo F; Llatjós M; Avila M; Margelí M; Serrano L; Centeno C; Quiroga V; Torky M; Ruiz-Manzano J
Cytopathology; 2018 Feb; 29(1):35-40. PubMed ID: 29119620
[TBL] [Abstract][Full Text] [Related]
18. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
Badowska-Kozakiewicz A; Sobol M; Patera J
Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
